VRAYQ
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado. On July 16, 2023, ViewRay, Inc., alongwith its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. On October 26, 2023, the voluntary petition of ViewRay , Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on July 16, 2023.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2023 Q1 | -0.16 | $23M | -$55M |
| 2022 Q4 | -0.15 | $35M | -$23M |
| 2022 Q3 | -0.14 | $26M | -$15M |
| 2022 Q2 | -0.15 | $22M | -$23M |
| 2022 Q1 | -0.14 | $19M | -$34M |
| 2021 Q4 | -0.16 | $20M | -$6M |
| 2021 Q3 | -0.15 | $19M | -$16M |
| 2021 Q2 | -0.19 | $15M | -$14M |